There’s a certain kind of credibility that only comes from having been in the trenches. Not the kind you manufacture with a polished investor deck or a list of buzzwords. The kind you earn by being present, year after year, when the industry blew up, broke down, pivoted, consolidated, and somehow came out the other side bigger and wilder than before.
Legacy DNA launched in 2010. If you were working in healthcare that year, you know exactly what the air felt like. Electric. Noisy. Equal parts terrifying and full of possibility.
The Affordable Care Act had just been signed, and the industry was reacting the way it always does to seismic change: loudly, and mostly without a plan. Providers were terrified. Payers were recalculating everything. Pharma was racing to understand what the new rules would mean for pipelines and the bottom line.
Quietly, in the background, a handful of leaders, the ones paying close attention, were already looking past the noise toward what came next.
That’s where Legacy DNA planted its flag. Transforming excitement and noise into strategy. And we’ve been there ever since.
While most of the industry was still arguing about what the ACA meant (and trust us, everyone had an opinion), one of our early clients was already moving. As Accountable Care Organizations launched in 2011 and value-based care frameworks started replacing fee-for-service logic, we were already fluent in the language, helping clients interpret pay-for-performance business models and position their businesses accordingly before the ink on the legislation was dry. Not because we had a crystal ball, but because we had the discipline to look at where the market was going and help our clients move before it was obvious.
That work became a template. By 2013, when the healthcare exchanges opened and nearly 17 million newly insured Americans entered the market, the clients who had moved early were positioned to grow into that wave rather than get flattened by it. We were helping healthcare companies refine their positioning, shape their go-to-market strategies, and align their growth efforts to absorb that demand. This helped ensure they wouldn’t simply survive the ACA transition; they could actually win in it.
When the model is new and the category is still forming, there’s no clear language and no established way to communicate value. We were helping clients define that in real-time, shaping how they showed up to a market that didn’t yet know how to evaluate them.
The companies that benefited most weren’t the ones who waited for clarity. They were the ones who moved early, aligned to where incentives were going, and built before the market caught up.
Then specialty pharmacy showed up on everyone’s radar. And it showed up loud.
Sovaldi launched in 2013. One pill. Eighty-four thousand dollars per treatment course. Before it, Hepatitis C treatment was a months-long ordeal of complex multi-drug regimens with significant side effects that made adherence and compliance a genuine clinical challenge. Sovaldi was a breakthrough by every measure. The price tag made sure nobody could ignore it.
Suddenly, organizations that had barely thought about specialty pharmacy found it sitting at the top of their cost reports, and an industry that barely had a definition was about to become the most talked-about real estate in healthcare.
We were already building strategic marketing relationships in the specialty pharmacy space, which at the time felt a little like showing up early to a party nobody else knew was happening. We worked with specialty pharmacies on bold changes in marketing (just say ‘no’ to gray scrubs on marketing brochures) and growth strategy.
And we helped them think through differentiation, how patient experience and access needed to be designed, and what it actually meant to build sustainable margin in a sector where everything was expensive, everything was complicated, and the rules had a habit of changing before you finished reading them.
Some of those clients didn’t just grow through this period. They became attractive acquisition targets because of how well-positioned they had become. We helped them get there, and in several cases, helped them navigate what came next.
While most organizations were reacting to cost pressure, a smaller group used that moment to redesign access, margin, and positioning. That’s where the real value was created.
The PE consolidation wave in specialty pharmacy and health tech was anything but subtle. Between 2017 and 2020, the sector saw an aggressive run of acquisitions, roll-ups, and platform builds as private equity firms recognized what the revenue concentration in specialty drugs actually meant for enterprise value. It was a fascinating, high-stakes, occasionally breathless period, and one we were built for.
Clients were no longer just asking how to grow. They were asking how to build companies worth buying, worth rolling up, worth taking to market. Exit strategy became part of the conversation. We were helping healthcare founders and executives think about enterprise architecture, EBITDA quality, and strategic positioning through a PE lens long before a banker ever showed up. For a number of those clients, the work paid off exactly as intended: growth realized, acquisitions completed, and multiples achieved on their terms.
One engagement from that period stands out. And unlike Steven Spielberg's AI movie, this story had a happy ending.
We engaged with an AI-based predictive analytics company that had built something genuinely ahead of its time: a platform that optimized the delivery of high-cost specialty medication shipments, identifying at-risk packages before they were lost, damaged, or delayed and saving millions of dollars in the process. Most people in the industry were still figuring out what a specialty tier was. This company was already using machine learning to protect some of the most expensive shipments in healthcare. We supported their strategic marketing, helped them take market share from an incumbent and navigate PE interest, and worked alongside them through the merger and acquisition. A company with genuinely transformative technology, finally getting the recognition and outcome it deserved.
The technology wasn’t the hardest part. Translating what it meant into something the market could understand, trust, and act on was. That’s where most early-stage innovation breaks down.
COVID-19 was not an inflection point. It was a detonation. Telehealth utilization exploded practically overnight. Drug supply chains buckled. Specialty pharmacy home delivery became essential infrastructure. And mRNA vaccine logistics became the most complex pharmaceutical distribution challenge in U.S. history, executed in months by an industry that had never done anything like it before.
For most organizations, the pivot to virtual operations was jarring, disorienting, and expensive. For us, it was Tuesday. We had been operating as a fully virtual firm for a decade, distributed by design, built around outcomes rather than office space. When the world went remote, we didn’t miss a beat, and neither did our clients.
The companies that came out stronger didn’t just adapt. They used the moment to accelerate changes they had been hesitating to make.
Digital health funding peaked at $29 billion in 2021 and then corrected sharply, separating real businesses from well-funded concepts that had never been stress-tested. Turns out, a Zoom visit and a great pitch deck are not the same thing as a sustainable business model. Who knew?
When the market corrected, it didn’t create new problems. It exposed the ones that had always been there.
PE consolidation in pharmacy accelerated hard: more roll-ups, more platform builds, more founder exits. Healthcare services M&A hit record volume in 2021 and 2022, and we were in the middle of it, helping leaders understand what their businesses were actually worth, what acquirers were really looking for, and how to close the gap between the two. When interest rates rose and deal flow cooled in 2023, the businesses that had done that work were still in a strong position. The ones counting on multiple expansions to do the heavy lifting were having some uncomfortable conversations.
Valuation compressions had a way of forcing honesty. Suddenly EBITDA quality mattered again. Strategic positioning mattered again. That’s always been the work we do best, and frankly, it’s a lot more fun when the stakes are high.
AI moved from a talking point to an operational differentiator. Ambient clinical documentation reduced physician administrative burden in measurable ways. AI-assisted prior authorization and revenue cycle management started showing real ROI. For the first time, the technology was actually doing what the pitch decks had promised.
This is the same pattern again. The difference is speed. The companies that win won’t be the ones with the most advanced models. They’ll be the ones who make their value clear, credible, and actionable faster than the rest of the market.
When Humira biosimilars launched in 2023, the industry expected a clean disruption story. It was messier than that. PBM rebate structures slowed adoption. Formulary design lagged the science. And specialty pharmacy independents were already under mounting pressure from vertically integrated PBM-owned competitors. For many of them, the question was no longer how to grow. It was whether to grow, sell, or find a partner before the window closed.
We helped them answer it.
Every one of these moments felt like disruption at the time.
Most companies experienced them as a risk. A smaller group experienced them as an opportunity. The difference wasn’t luck. It was how they interpreted what was happening and how quickly they moved.
That pattern hasn’t changed. The speed has.
Medicare is now negotiating drug prices directly for the first time in history. Biosimilars are on track for automatic interchangeable status. Cost-plus pharmacy models are disrupting PBM contracts. AI is moving from experimentation to tactical deployment inside real clinical and operational workflows, and this time, we’ve seen this movie before.
We have been through every version of this industry: the regulatory upheavals, the pricing controversies, the PE waves, the tech booms, the recessions. We have sat across the table, virtually and otherwise, from health system executives, specialty pharmacy leaders, and healthcare company founders in markets that were transforming underneath their feet. We have helped them grow, adapt, and build companies that became attractive to the right buyers at the right time.
Sixteen years in. The landscape looks nothing like it did in 2010. And yet the core challenge has never changed: build something real, grow it intelligently, and know where you’re going before the market decides for you.
Every major shift in healthcare creates a window where value is built quickly and unevenly. We’ve seen this play out again and again. The question isn’t whether AI will change the market. It’s who will move early enough to benefit from it.
Credibility comes from operating inside periods of change—not just observing them. Leaders who have navigated regulatory shifts, market disruptions, and evolving care models firsthand are better equipped to make decisions when the path forward isn’t clear.
Success comes from turning uncertainty into strategy. Organizations that interpret change early, refine their positioning, and align their go-to-market approach ahead of the market are the ones that grow while others are still reacting.
The companies that win are not necessarily the ones with the best ideas—they’re the ones that interpret market signals correctly and act faster than competitors. Speed of execution consistently separates opportunity from risk.
Specialty pharmacy introduced complex cost, access, and margin challenges that forced organizations to rethink patient experience, differentiation, and sustainability—creating new opportunities for those who adapted early.
Preparation goes beyond growth alone. Companies that are most attractive to buyers focus on building enterprise value through clear positioning, scalable operations, and a strategic narrative that holds up under diligence.
When markets tighten, fundamentals matter. Companies with clear positioning, strong EBITDA quality, and aligned growth strategies remain resilient, while those relying on momentum alone face valuation pressure.
Every major disruption creates a window where value is built quickly—but unevenly. The consistent advantage goes to leaders who act early, build intentionally, and align their strategy to where the market is going, not where it’s been.
